[go: up one dir, main page]

US20020179102A1 - System for effecting smoke cessation - Google Patents

System for effecting smoke cessation Download PDF

Info

Publication number
US20020179102A1
US20020179102A1 US10/174,000 US17400002A US2002179102A1 US 20020179102 A1 US20020179102 A1 US 20020179102A1 US 17400002 A US17400002 A US 17400002A US 2002179102 A1 US2002179102 A1 US 2002179102A1
Authority
US
United States
Prior art keywords
nicotine
formulation
patient
containers
aerosolizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/174,000
Other languages
English (en)
Inventor
Stephen Farr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aradigm Corp
Original Assignee
Aradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aradigm Corp filed Critical Aradigm Corp
Priority to US10/174,000 priority Critical patent/US20020179102A1/en
Assigned to ARADIGM CORPORATION reassignment ARADIGM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FARR, STEPHEN J.
Publication of US20020179102A1 publication Critical patent/US20020179102A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
    • A24F40/42—Cartridges or containers for inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment

Definitions

  • This invention relates generally to a method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of nicotine to effect smoking cessation.
  • Smoking a cigarette delivers nicotine vapors to the lungs, where nicotine is rapidly absorbed through the arteries and delivered to the brain. Nicotine interacts with nicotinic cholinergic receptors in the brain to induce the release of neurotransmitters and produce an immediate reward—the “rush” that smokers experience—that is associated with a rapid rise in blood level. A persistent stimulus is also produced, and is associated with a high blood level of nicotine. Complex behavioral and social aspects of smoking, e.g., the hand-to-mouth ritual, etc., are also habit-forming.
  • a therapeutic approach to aid in smoking cessation is to provide the smoker with nicotine from sources other than cigarettes.
  • a number of nicotine replacement therapies have been developed to accomplish this result.
  • Commercially available therapies deliver nicotine to the systemic circulation via absorption through mucosal membranes or the skin. These include nicotine-containing chewing gum, sachets, transdermal patches, capsules, tablets, lozenges, nasal sprays and oral inhalation devices.
  • Nicotine delivery via inhalation offers the benefit of addressing the psychological component of cigarette smoking in addition to the physiological dependence on nicotine.
  • Nicotine inhalation systems release nicotine as a vapor (see U.S. Pat. Nos. 5,167,242; 5,400,808; 5,501,236; 4,800,903; 4,284,089; 4,917,120; 4,793,366), aerosol (see U.S. Pat. Nos. 5,894,841; 5,834,011) or dry powder (see U.S. Pat. No. 5,746,227) when air is inhaled through the inhaler.
  • a droplet ejection device U.S. Pat. No. 5,894,841 has also been described that delivers a controlled dose of nicotine via inhalation.
  • These systems deliver low doses of nicotine to the mouth and throat, where nicotine is absorbed through the mucosal membranes into the circulation.
  • Some inhalation therapies feature devices that simulate or approximate the look, feel and taste of cigarettes.
  • a system for aiding a patient in quitting smoking is disclosed.
  • the system is comprised of a means for the delivery of aerosolized nicotine which makes it possible to gradually decrease the amount of nicotine that the patient receives.
  • the system comprises a means for aerosolizing a formulation comprised of nicotine and a means for decreasing the amount of nicotine formulation which is aerosolized and/or the amount which actually reaches the patient's circulatory system.
  • the amount of nicotine aerosolized or effectively delivered to the patient can be changed in several different ways using either the device aerosolization mechanism, the formulation or formulation containers loaded into the device.
  • a preferred system of the invention aerosolizes the liquid formulation by applying force to a container of nicotine formulation and causing the nicotine formulation to be moved through a porous membrane which results in creating particles of nicotine formulation which are inhaled by the patient.
  • This system modifies the amount of nicotine aerosolized by providing a plurality of different containers or different groups of containers wherein the different containers or groups of containers contain different concentrations of nicotine.
  • a patient using the system can utilize packets of nicotine formulation containing a high concentration initially and then gradually switch towards lower and lower concentrations so that the patient receives essentially the same amount of aerosolized formulation but receives gradually reduced amounts of nicotine due to the reduced concentration of the nicotine in the formulation.
  • the same procedure described above can also be carried with a dry powder inhaler (DPI).
  • DPI dry powder inhaler
  • the packets of dry powder nicotine formulation loaded into the device can initially contain a relatively high concentration of nicotine. Thereafter, the concentration of nicotine in the dry powder formulation added into the device is gradually decreased.
  • MDI metered dose inhaler
  • MDI metered dose inhaler
  • the desired result of reducing the amount of nicotine delivered to the patient can be obtained.
  • the same results could be obtained by gradually decreasing the amount of formulation released when the value of a container is opened.
  • a dry power inhaler or a system which aerosolizes a liquid formulation by moving the formulation through a porous membrane it is possible to decrease the amount of nicotine gradually by making changes in the device, or more specifically the operation of the device.
  • a dry powder inhaler often utilizes a burst of air in order to aerosolize the dry powder.
  • the burst of air could be decreased so that not all of the powder is fully aerosolized or so that the powder is not aerosolized in a completely efficient manner.
  • the system for aerosolizing liquid formulation is adjusted at different points so that different amount of pressure are applied to the formulation making it possible to aerosolize decreasing amounts of formulation and allowing the patient to be gradually weaned off of nicotine.
  • the most preferred embodiment of the invention involves the use of a system which aerosolizes liquid formulations of nicotine contained within individual packets which packets include a porous membrane.
  • the amount of nicotine that can be changed by changing the amount of or concentration of nicotine in the packets.
  • the pore size is in a preferred range then a relatively high concentration of the formulation aerosolized will reach the patient's lungs and move from the lungs into the patient's circulatory system.
  • the pores larger the aerosolized particles created also become larger. The larger particles will not move into the lungs as efficiently as the smaller particles.
  • the larger particles may be deposited in areas where they are not readily absorbed into the patient's circulatory system.
  • a plurality of different containers are produced.
  • the containers are different from each other in that they contain different amounts or concentrations of nicotine.
  • the containers are different from each other in that they have different porous membranes on them which make it possible to aerosolize the formulation in a somewhat less efficient manner over time. It is possible to combine both or all three features together. More specifically, it is possible to produce containers which contain (1) smaller concentrations of nicotine; (2) smaller amounts of nicotine; or (3) have porous membranes which have different size or amounts of pores so as to less efficiently aerosolize the formulation present in the container.
  • a method for aiding in smoking cessation and for treating conditions responsive to nicotine therapy by the administration of nicotine is disclosed.
  • a formulation comprised of nicotine is aerosolized.
  • the aerosol is inhaled into the lungs of the patient. Once inhaled, particles of nicotine deposit on lung tissue and from there enter the patient's circulatory system. Because delivery is to the lungs, the patient's serum nicotine level is quickly raised to a desired level—as quickly as if the user were smoking.
  • the methods of the invention produce arterial concentrations of nicotine similar to cigarette smoking.
  • the patient's dependence on nicotine is reduced by gradually reducing the dose of nicotine.
  • the dose of nicotine is reduced by progressively increasing the size distribution of the aerosolized nicotine particles delivered to the patient. This decreases the amount of nicotine delivered to the patient's lungs, with the result that nicotine absorption is less immediate and the blood plasma level is lower.
  • a method of treatment comprising:
  • the method is preferably further comprised of:
  • An aspect of the invention is a method of treatment whereby nicotine or a nicotine substitute is aerosolized, inhaled into areas of the respiratory tract including the lungs and provided to the circulatory system of the patient at levels sufficient to simulate cigarette smoking.
  • An advantage of the invention is that the nicotine levels are raised almost immediately on administration.
  • Another advantage of the invention is that the patient can gradually be weaned off of the immediate effect of nicotine obtained via smoking and gradually weaned off of the need of nicotine by, respectively, increasing particle size and decreasing dose size or concentration.
  • a feature of the invention is that aerosolized particles of nicotine having a diameter of about 0.5 to 8 microns ( ⁇ ) are created and inhaled deeply into the lungs, thereby enhancing the speed and efficiency of administration.
  • An aspect of the invention is a method whereby larger and larger particles of aerosolized nicotine are administered to a patient over time in order to first wean a smoking patient off of the addiction to immediate nicotine and thereafter reduce the amount of nicotine in order to wean the patient completely off of the addiction to nicotine, thereby allowing the patient to quit smoking.
  • a feature of this invention is that it allows for the formation of nicotine particles in different sizes designed for delivery to different areas of a patient's lungs.
  • An advantage of the invention is that it allows the patient to be weaned off of (1) the need for immediate nicotine delivery as obtained when smoking, and (2) the need for nicotine at all.
  • FIG. 1 is a schematic view of a human lung branching pattern.
  • FIG. 2 is a schematic view of a human respiratory tract.
  • nicotine is intended to mean the naturally occurring alkaloid known as nicotine, having the chemical name S-3-(1-methyl-2-pyrrolidinyl)pyridine, which may be isolated and purified from nature or synthetically produced in any manner.
  • Nicotine is a colorless to pale yellow, strongly alkaline, oily, volatile, hygroscopic liquid having a molecular weight of 162.23 and the formula:
  • Nicotine is approximately 10% of the particulate weight in cigarette smoke. Brand differences change this percentage. It is monoprotonated at most physiological pH values. The diprotonated ion would exist at pH values found in the stomach. Metabolism is largely due to oxidation. Cotinine is a major metabolite; however, there are at least 4 primary metabolites of nicotine and all are encompassed by the use of this term herein.
  • the term “nicotine” further includes any pharmacologically acceptable derivative, metabolite or analog of nicotine which exhibits pharmacotherapeutic properties similar to nicotine.
  • Such derivatives and metabolites are known in the art, and include cotinine, norcotinine, nornicotine, nicotine N-oxide, cotinine N-oxide, 3-hydroxycotinine and 5-hydroxycotinine or pharmaceutically acceptable salts thereof
  • a number of useful derivatives of nicotine are disclosed within the Physician's Desk Reference (most recent edition) as well as Harrison's Principles of Internal Medicine. In addition, applicants refer to U.S. Pat. Nos.
  • the physiologically active form of nicotine is the S-(-)-isomer.
  • Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, R and S enantiomers, diastereomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • upper airways and the like are used interchangeably herein to define an area of the respiratory system which includes the oropharyngeal region and trachea. This area is the first area which air enters upon inhalation (see FIG. 1).
  • central airways bronchial airways
  • bronchial airways and the like are used interchangeably herein to refer to a region of the respiratory system that includes generations 1 through 16 of the airways (see FIG. 1) which removes particles larger than 3 ⁇ in diameter. They are the conductive airways that also clean particles from the lung using a mucosal clearance mechanism. Upon inhalation, air passes through the upper airways into the central airways.
  • pulmonary region The terms “pulmonary region,” “peripheral region” and the like are used interchangeably herein to define a region of the respiratory system where gas exchange occurs between the lungs and the circulatory system, i.e., where oxygen enters the blood and carbon dioxide leaves the blood.
  • the peripheral region includes generations 17 through 23 of the airways (see FIG. 1). Drugs delivered to this area generally have a systemic effect.
  • alveolar ducts refer to components in the pulmonary region of the lung which are approximately 3 ⁇ in diameter where gas exchange occurs between the air in the lungs and the circulatory system.
  • the term “diameter” is used herein to refer to particle size as given in the “aerodynamic” size of the particle.
  • the aerodynamic diameter is a measurement of a particle of unit density that has the same terminal sedimentation velocity in air under normal atmospheric conditions as the particle in question. This is pointed out in that it is difficult to accurately measure the diameter of small particles using current technology and the shape of such small particles may be continually changing. Thus, the diameter of one particle of material of a given density will be said to have the same diameter as another particle of the same material if the two particles have the same terminal sedimentation velocity in air under the same conditions. In connection with the present invention, it is important that particles, on average, have the desired diameter so that the particles can be inhaled and targeted to a specific area of the lungs.
  • An acceptable range for particle diameter varies depending on the area of the respiratory tract being targeted.
  • the particles should have a diameter in a range of about 0.5 ⁇ to about 2 ⁇ .
  • the diameter should be in the range of from about 2 ⁇ to about 4 ⁇ , and to target the small bronchi and above the particles should have a diameter of from about 4 ⁇ to about 8 ⁇ .
  • porous membrane shall be interpreted to mean a membrane of material in the shape of a sheet having any given outer perimeter shape, but preferably covering a package opening which is in the form of an elongated rectangle, wherein the sheet has a plurality of openings therein, which openings may be placed in a regular or irregular pattern, and which openings have a diameter in the range of 0.25 ⁇ to 4 ⁇ and a pore density in the range of 1 ⁇ 10 4 to about 1 ⁇ 10 8 pores per square centimeter.
  • the porous membrane may be merely an area of the package which has pores therein wherein the pores have a size and a density as described above.
  • the configuration and arrangement of the pore density may be changed so as to provide pores which are capable of creating the desired amount of aerosol.
  • the porous membrane or area of the container may have some 10 to 10,000 pores therein which pores are positioned in an area of from about 1 mm 2 to about 1 Cm 2 .
  • the membrane is preferably comprised of a material having a density in the range of 0.25 to 3.0 mg/Cm 2 , more preferably 1.7 mg/Cm 2 , and a thickness of about 2 ⁇ to 20 ⁇ , more preferably about 8 ⁇ to 12 ⁇ .
  • the membrane material is preferably hydrophobic and includes materials such as polycarbonates and polyesters which may have the pores formed therein by any suitable method including anisotropic etching or by etching through a thin film of metal or other suitable material. Pores can be created in the membrane which may be an area of the container by use of techniques such as etching, plating or laser drilling.
  • the membrane materials may have pores with a conical configuration and have sufficient structural integrity so that it is maintained intact (will not rupture) when subjected to force in the amount of about 20 to 200 psi while the formulation is forced through the pores.
  • the membrane functions to form an aerosolized mist when the formulation is forced through it.
  • Those skilled in the art may contemplate other materials which achieve this function as such materials are intended to be encompassed by this invention.
  • treatment used interchangeably herein to generally mean obtaining a desired pharmacological and/or physiological effect.
  • the terms are used in a manner somewhat differently than the terms are typically used in that what is intended by the method of treatment of the invention is to allow a patient to overcome an addiction to nicotine and thereby allow the patient to quit smoking.
  • the treating effect of the invention provides a psychological effect in that the invention originally delivers high doses of nicotine in a manner that simulates the nicotine delivery obtained from a cigarette. The patient then becomes accustomed to relying on the methodology of the invention to provide an immediate “rush” of nicotine. Thereafter, the particles of the aerosol are made larger.
  • the treatment of the invention reduces the amount of nicotine so as to allow the patient to completely “wean” off of nicotine and to quit smoking.
  • the steady state delivery of nicotine as therapy for smokers wishing to quit is characterized by slow absorption and low blood levels of nicotine, which limits its utility.
  • the present invention replaces the nicotine that a smoker receives from smoking a cigarette in a therapeutically effective manner by providing a rapid pulse of bioavailable nicotine to the smoker on demand.
  • intravenous administration One means currently available for a true pulsatile, rapid onset replacement therapy is intravenous administration. Although preparations of nicotine appropriate for intravenous administration have been available for some time, intravenous cannulation as a means for gaining access to the circulation for the administration of nicotine on demand is not a socially acceptable alternative to cigarette smoking.
  • the treatment methodology of the present invention creates an aerosol of nicotine particles.
  • the nicotine particles may be formed from any liquid containing nicotine including a solution or suspension of nicotine and aerosolized in any known manner including (1) moving the formulation through a porous membrane in order to create particles or (2) a dry powder where the particles of powder have been designed to have a desired diameter.
  • the rate of particle absorption is directly proportional to the surface area of the tissue on which the particles are deposited. Accordingly, nicotine is absorbed more slowly through the mucosal membranes of the upper respiratory tract which have a smaller surface area than through the airways in the lower respiratory tract which have a larger surface area.
  • the overall effect of increasing the size of the nicotine particles is to reduce the rate at which nicotine is absorbed into the circulation, thereby reducing the smoker's physiological dependence on the quick rush of nicotine experienced when smoking.
  • the penetration of aerosolized nicotine particles into the respiratory tract is determined largely by the size distribution of the particles formed. Larger particles, i.e., particles with a diameter ⁇ 5 ⁇ , deposit on the upper airways of the lungs (see FIG. 1). Particles having a diameter in a range of about >2 ⁇ to ⁇ 5 ⁇ penetrate to the central airways. Smaller particles having a diameter ⁇ 2 ⁇ penetrate to the peripheral region of the lungs.
  • the treatment methodology begins with particles of a given size, carries out treatment for a given period of time after which the particles are increased in size.
  • the particles initially administered to the patient penetrate deeply into the lung, i.e., the smallest particles (e.g. 0.5 to 2 ⁇ ) target the alveolar ducts and the alveoli.
  • the deepest part of the lung is targeted with the smallest particles the patient receives an immediate “rush” from the nicotine delivered which closely matches that received when smoking a cigarette.
  • These small particles can be obtained by milling powder into the desired size and inhaling the powder or by creating a solution or suspension and moving the solution or suspension through the pores of a membrane.
  • the desired result is to obtain particles which have a diameter in the range of 0.5 ⁇ to about 2 ⁇ .
  • Those skilled in the art will understand that some of the particles will fall above and below the desired range. However, if the majority of the particles ( 50% or more) fall within the desired range then the desired area of the lung will be correctly targeted.
  • the patient is allowed to continually, from time to time, target the outermost area of the lung with the smallest particles. For example, the patient would be instructed to repeatedly administer the smallest size particles when the patient would normally smoke a cigarette. In this manner, the patient will become accustomed to finding that the device administers nicotine into the patient in the same manner that a cigarette does.
  • the concentration of the nicotine in the liquid formulation could be reduced gradually over time. This could be done over a sufficiently long period of time so as to allow the patient to “wean” off of nicotine.
  • the amount of nicotine is kept substantially constant but the size of the aerosolized particles created are increased.
  • the second phase of the treatment methodology is to increase the size of the particles so as to target the respiratory tract above the alveolar ducts and below the small bronchi.
  • This can generally be accomplished by creating aerosolized particles of nicotine which have a size and range of about 2 ⁇ to about 4 ⁇ .
  • Administration is carried out in the same manner as described above. Specifically, the patient administers the aerosolized nicotine at the same time when the patient would be smoking a cigarette. Since the patient has become adjusted to receiving the nicotine “rush” from the smaller sized particles, the patient will expect and is therefore likely to experience the same “rush” when administering the slightly larger particles. However, the effect will be less immediate.
  • This procedure is carried out over a period of time, e.g., days or weeks. In one embodiment of the invention it is possible to reduce the dose of aerosolized nicotine delivered to the patient during this second phase. However, the dose may remain constant.
  • the treatment can be completed after any phase, e.g. after the second phase.
  • a third phase of treatment is carried out.
  • the particles are increased to a size in a range from about 4 ⁇ to about 8 ⁇ or, alternatively, perhaps as large as 12 ⁇ .
  • These larger particles will target the upper airways.
  • the larger particles will give a very small immediate “rush” but will still be absorbed through the mucous membranes of the patient's respiratory tract.
  • the patient will be administering nicotine doses which may be the same as those doses administered at the beginning of treatment.
  • the treatment can take a number of different directions.
  • the patient can attempt to stop administration by immediate and complete cessation of nicotine delivery.
  • the patient can try to wean off of nicotine by delivering fewer doses during a given time period.
  • the same size dose volume of aerosol formulation
  • the same size dose is administered and delivered, creating the same amount of aerosol, but wherein the aerosolized particles contain progressively less nicotine (i.e., more dilute concentration).
  • the amount of nicotine can be decreased until the patient is receiving little or no nicotine.
  • the invention is particularly suited for smokers in that smokers are accustomed to inhaling their source of nicotine.
  • Other treatments such as those involving the transdermal delivery of nicotine via a nicotine “patch” or buckle delivery via a nicotine “gum” do not match the means which a smoker usually obtains nicotine.
  • the present invention provides a method wherein the patient obtains an influx of nicotine into the circulatory system at a rate which substantially matches the rate which nicotine would enter the circulatory system when smoking. This is obtained because, at least at first, the invention provides sufficiently small particles such that they are inhaled deeply into the lung, i.e. 50% or more of the particles are inhaled deeply into the lung and thereby quickly enter the patient's circulatory system.
  • the present invention is advantageous in that the rate at which the delivered nicotine enters the circulatory system can be gradually decreased by gradually increasing the size of the aerosolized particles delivered to the patient. This can be done over any desired period of time and in any desired number of phases.
  • the invention provides a means whereby the amount of nicotine delivered to the patient can be gradually decreased in a number of different ways. Firstly, it can be decreased by decreasing the concentration of nicotine in the aerosolized formulation. Secondly, it can be decreased by merely decreasing the number of administrations of aerosolized doses. Thirdly, it can be decreased by decreasing the size of the dose aerosolized and inhaled by the patient.
  • One aspect of the invention is a method of treatment, comprising:
  • the particles targeting this area will have a relatively small size, e.g. 0.5 micron to about 2 microns in diameter.
  • (b) in the next step the patient inhales the aerosolized particles of (a) into the respiratory tract, preferably targeted to a specific area of the lower respiratory tract where the deposited particles cross into the patient's circulatory system.
  • steps (a) and (b) are repeated a plurality of times. Specifically, the patient may repeat these steps any number of times such as every time the patient would normally smoke a cigarette. At this point the patient could continue the treatment protocol in this manner and gradually decrease the number of times the patient administers aerosolized nicotine until the patient is no longer addicted to nicotine. Decreasing the amount of aerosolized nicotine could also be done by decreasing the concentration of nicotine within the aerosolized particles decreasing the concentration of nicotine in the formulation and/or decreasing the size of the aerosolized dose.
  • step (d) which involves aerosolizing formulation comprised of nicotine in order to create aerosolized particles which are larger in size than the aerosolized particles produced in step (a).
  • aerosolizing formulation comprised of nicotine in order to create aerosolized particles which are larger in size than the aerosolized particles produced in step (a).
  • These larger particles are directed towards a particular area of the patient's respiratory tract, e.g. the mid-region of the patient's respiratory tract. (See FIGS. 1 and 2)
  • These particles could have a size in the range of about 2 microns to about 4 microns.
  • step (d) the patient inhales the aerosolized particles of (d) thereby targeting the particular desired area of the patient's respiratory tract such as the mid region.
  • steps (d) and (e) are repeated a plurality of times.
  • the patient can decrease the amount of nicotine being delivered as indicated in the same manner as indicated above step (c).
  • the method of the invention can be continued so that a third phase of treatment can be carried out which phase is similar to the two phases described above.
  • the treatment could involve as many as 24 phases which target specific defined regions of a patients respiratory tract using particles which are continually larger in size in each of the 24 phases (see FIG. 1 and Table 1 below). Because it may not be practical to specifically design the particles so that they are all larger in each of the phases the formulations may be designed so that a certain percentage of the particles within each phase of delivery is larger than the particles in the preceding phase.
  • the method of the invention can be carried out using 1 to 24 different phases with each phase targeting a higher level of the respiratory tract (See Table 1).
  • the higher levels of the respiratory tract can be targeted using larger and larger particles.
  • TABLE 1 Subdivision of the Respiratory Tree Generation Name 0 Trachea 1 Primary bronchi 2 Lobar bronchi 3 Segmental bronchi 4 subsegmental bronchi 5 Small bronchi ⁇ 10 11 Bronchioles, primary and secondary ⁇ 13 14 Terminal bronchioles ⁇ 15 16 Respiratory bronchioles ⁇ 18 19 Alveolar ducts ⁇ 23 24 Alveoli
  • a nicotine formulation is forced through the openings or pores of a porous membrane to create an aerosol.
  • the openings are all uniform in size and are positioned at uniform distances from each other.
  • the openings can be varied in size and randomly placed on the membrane. If the size of the openings is varied, the size of the particles formed will also vary. In general, it is preferable to maintain uniform opening sizes in order to create uniform particle sizes, and it is particularly preferable to have the opening sizes within the range of about 0.25 ⁇ to about 6 ⁇ which will create particle sizes of about 0.5 ⁇ to 12 ⁇ which are preferred with respect to inhalation applications.
  • the openings When the openings have a pore size in the range of 0.25 ⁇ to 1 ⁇ they will produce an aerosol having particle sizes in the range of 0.5 ⁇ to 2 ⁇ , which is particularly useful for delivering nicotine to the alveolar ducts and alveoli. Pore sizes having a diameter of about 1 ⁇ to 2 ⁇ will produce particles having a diameter of about 2 ⁇ to 4 ⁇ , which are particularly useful for delivering nicotine to the area above the alveolar ducts and below the small bronchi. A pore size of 2 ⁇ to 4 ⁇ will create particles having a diameter of of 4 ⁇ to 8 ⁇ , which will target the area of the respiratory tract from the small bronchi upward.
  • the size of the aerosolized nicotine particles is increased in a stepwise manner by using porous membranes that create “monodisperse” aerosols, wherein all the particles within the aerosol created have essentially the same particle size. Nicotine particles of increasing size are produced by using membranes of increasing pore sizes.
  • the size of the aerosolized nicotine particles is increased in gradient fashion by using porous membranes that create “multi-disperse” aerosols, wherein the particles within the aerosol created have different particle sizes.
  • Membranes which have an increasing range of pore sizes are used to produce nicotine particles of increasing size.
  • Nicotine can be administered orally. However, after oral administration it is absorbed from the gut into the portal blood and degraded promptly by the liver. Thus, insignificant amounts reach the patient's systemic circulation. Nicotine can also be administered parenterally. However, when so administered it is rapidly absorbed and metabolized making it difficult to sustain therapeutic levels in plasma over time. In view of such, effective therapy has been carried out using other means of delivery (e.g., transdermal patches, gum).
  • the present invention uses intrapulmonary delivery to avoid first pass liver metabolism and to obtain quick infusion into the patient's systemic circulatory system. The present invention administers sufficient nicotine by inhalation to temporarily produce a rapid increase in the patient's blood level, and thereafter allow the patient's nicotine level to return to a therapeutically effective level.
  • the amount of drug aerosolized will be greater than the amount that actually reaches the patient's circulation. For example, if the inhalation system used is only 50% efficient then the patient will aerosolize a dose which is twice that needed to raise the patient's nicotine level to the extent needed to obtain the desired results. More specifically, when attempting to administer 1 mg of nicotine with a delivery system known to be 50% efficient, the patient will aerosolize an amount of formulation containing about 2 mg of nicotine.
  • a device comprised of a container that includes an opening covered by a porous membrane, such as the device disclosed in U.S. Pat. No. 5,906,202, may be used to deliver nicotine.
  • the device may be designed to have the shape and/or bear the markings of a pack of cigarettes, and may include the scent of tobacco.
  • Cigarettes contain 6 to 11 mg of nicotine, of which the smoker typically absorbs 1-3 mg; see Henningfield N Engl J Med 333:1196-1203 (1995).
  • Factors influencing nicotine absorption include subject-dependent factors, such as smoking behavior, lung clearance rate, etc., morphological factors, and physiological factors, such as tidal volume, inspiratory and expiratory flow rate, particle size and density. See Darby et al., Clin Pharmacokinet 9:435-439 (1984).
  • the systemic dose of nicotine per puff is extremely variable, however, peak plasma concentrations of 25-40 ng/mL of nicotine, achieved within 5-7 minutes by cigarette smoking, are believed typical.
  • 0.1 mg to 10 mg, preferably 1 to 3 mg, and more preferably about 2 mg of nicotine are delivered to the lungs of the patient in a single dose to achieve peak blood plasma concentrations of 15-40 ng/mL.
  • the amount of a nicotine administered will vary based on factors such as the age, weight and frequency of smoking or nicotine tolerance of the smoker. Other factors, such as daily stress patterns, demographic factors may also determine, in part, the amount of nicotine sufficient to satisfy the smoker's craving for nicotine.
  • Administering nicotine using the methods of the present invention can involve the daily administration of anywhere from 5 mg to 200 mg of nicotine, but more preferably involves the administration of approximately 10 to 100 mg per day.
  • nicotine can be administered in toxic amounts. Care should be taken not to overdose the patient.
  • the amount of nicotine which an individual can tolerate will vary on a number of factors including size, sex, weight and amount of cigarette smoking the patient is accustomed to.
  • a lock-out system into the delivery device which prevents administration of acrosolized doses beyond a given point.
  • Such a system is described within U.S. Pat. No. 5,735,263 issued Apr. 7, 1998 and incorporated herein by reference in its entirety to disclose drug delivery devices and lock-out systems used in connection therewith.
  • the nicotine is in a liquid form or is dissolved or dispersed within a pharmaceutically acceptable, liquid excipient material to provide a liquid, flowable formulation which can be readily aerosolized.
  • the container will include the formulation having nicotine therein in an amount of about 10 mL to 300 mL, more preferably about 200 mL.
  • the large variation in the amounts which might be delivered is due to different delivery efficiencies for different devices.
  • Administration may involve several inhalations by the patient, with each inhalation providing nicotine from the device.
  • the device can be programmed so as to release the contents of a single container or to move from one container to the next on a package of interconnected containers. Delivering smaller amounts from several containers can have advantages.
  • the patient is treated in the three different phases.
  • the aerosolized liquid particles or dry powder particles have a size and a range of 0.5 ⁇ to about 2 ⁇ .
  • the particles of nicotine having this size are administered in a dosage amount which is substantially equivalent to the doses or amount which the patient would received from a single cigarette or, alternatively, the dosage amount which the patient would received from a single puff on a single cigarette. Assuming that the patient receives the dosage amount of a single cigarette then the patient will be administered approximately 1 to 3 mg of nicotine each time the formulation is aerosolized.
  • the particles having a size of 0.5 ⁇ to about 2 ⁇ will be administered to the patient over a plurality of days (e.g., 2 to 7 days) or perhaps a plurality of weeks (e.g., 2 to 4 weeks). If the device and/or dosage containers are designed to deliver a dosage equivalent to a puff on a cigarette then substantially smaller doses are delivered. If each dose corresponds to a puff on a cigarette then a patient may be directed to continually take aerosolized doses equivalent to a cigarette puff over a period of one to ten minutes or any period of time equivalent to what that patient normally takes to smoke one cigarette. This constitutes the first phase of treatment.
  • the method of the invention may be completed. However, as indicated above the method may be continued by repeating phases such as the first phase using continually larger particles and/or continuing more dilute solutions of nicotine and/or smaller doses of nicotine.
  • the patient is preferably administered the same dosage amount of nicotine with each inhalation, e.g., the patient is administered 1 to 3 mg of nicotine each time formulation is aerosolized.
  • the size of the particles is increased to a size and range from 2 ⁇ to about 4 ⁇ .
  • the particle size is increased in order to target an area of the lungs where the nicotine will be absorbed into the circulatory system more slowly. Specifically, the larger particles target an area of the lungs above the alveolar ducts and below the small bronchi.
  • Administration is carried out over a plurality of days or a plurality of weeks in the same manner as indicated above.
  • the patient preferably administers nicotine from a device of the invention when the patient would normally smoke a cigarette.
  • the treatment can be completed pursuant to the present invention by using only the two phases. However, it is preferable to include three or more phases.
  • the same dose is administered each time nicotine formulation is aerosolized. Accordingly, 1 to 3 mg of nicotine is delivered to the patient at each dose. However, the dose is delivered by using aerosolized particles which have a diameter of 4 ⁇ or more, e.g., in the range of from 4 ⁇ to about 8 ⁇ . These larger particles are designed to target the area of the respiratory tract at the small bronchi or higher.
  • aerosolized particles which have a diameter of 4 ⁇ or more, e.g., in the range of from 4 ⁇ to about 8 ⁇ . These larger particles are designed to target the area of the respiratory tract at the small bronchi or higher.
  • the nicotine targets the upper airways it will not immediately enter the patient's circulatory system. However, the nicotine will, eventually, cross the mucous membranes of the upper respiratory tract and enter the circulatory system. Thus the patient will be administered nicotine but will become less accustomed to having the immediate “rush” obtained from smoking.
  • the third phase the patient has been weaned away from the need for the “rush” of nicotine.
  • the third phase is then used to continually reduce the number of administrations needed and thereby reduce the amount of nicotine administered.
  • the patient's dependency on nicotine is slowly reduced and then eliminated thereby allowing the patient to quit smoking.
  • the method of the invention has applicability to smokers wishing to quit or trying to quit who have experienced all or any of the nicotine withdrawal symptoms associated with smoking cessation, such as craving for nicotine, irritability, mood ability, frustration or anger, anxiety, drowsiness, sleep disturbances, impaired concentration, nervousness, restlessness, decreased heart rate, increased appetite and weight gain.
  • pulmonary administration of nicotine could be of value for the treatment of other diseases, such as for patients suffering from neurodegenerative diseases, psychiatric disorders and other central nervous system disorders responsive to nicotinic receptor modulation (see U.S. Pat. Nos. 5,187,169; 5,227,391; 5,272,155; 5,276,043; 5,278,176; 5,691,365; 5,885,998; 5,889,029; 5,914,328).
  • diseases include, but are not limited to, senile dementia of the Alzheimer's type, Parkinson's disease, schizophrenia, obsessive-compulsive behavior, Tourette's Syndrome, depression, attention deficit disorder, myasthenia gravis and drug addiction.
  • compositions can be produced as a colorless to pale yellow liquid.
  • the pure liquid could be aerosolized and inhaled by itself.
  • a formulation may include a buffer to enhance absorption. Any absorption enhancers including ammonia could be used with the formulation.
  • a typical formulation is only nicotine dissolved in water or dry powder nicotine.
  • Formulations of nicotine include aqueous formulations, aqueous saline formulations, and ethanol formulations. All of these formulations may be included with additional components such as permeation enhancers, buffers, preservatives and excipient and carrier components and additives normally included within formulations for aerosolized drug delivery.
  • Nicotine is freely soluble in water.
  • An aqueous nicotine solution may be readily aerosolized and inhaled.
  • the nicotine solution can be placed in a low boiling point propellant in a pressurized canister and released using a conventional metered dose inhaler (MDI) device.
  • MDI metered dose inhaler
  • the MDI device is modified so that the aerosolized dose is released each time at the same inspiratory flow rate and inspiratory volume. When this is done the patient is more likely to receive the same dose each time.
  • a device for obtaining repeating dosing with an MDI canister is taught in U.S. Pat. No. 5,404,871.
  • a dry powder formulation comprising a pharmacologically acceptable salt of nicotine alone or with additives such as components to prevent the particles from sticking together may be used.
  • Smokers wishing to quit may be treated solely with respiratory nicotine as indicated above, i.e. by intrapulmonary delivery. However, it is possible to treat such patients with a combination of pulmonary administration and other means of administration, such as transdermal administration. Transdermal nicotine is preferably administered to maintain a steady state level of nicotine within the circulatory system. Nasal or buccal formulation could be used for nasal or buccal delivery which could supplement aerosolized delivery.
  • a plurality of different treatments and means of administration can be used to treat a single patient.
  • a patient can be simultaneously treated with nicotine by transdermal administration, nicotine via pulmonary administration, in accordance with the present invention, and nicotine which is administered to the mucosa.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US10/174,000 1999-07-16 2002-06-17 System for effecting smoke cessation Abandoned US20020179102A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/174,000 US20020179102A1 (en) 1999-07-16 2002-06-17 System for effecting smoke cessation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14414099P 1999-07-16 1999-07-16
US61142300A 2000-07-07 2000-07-07
US10/174,000 US20020179102A1 (en) 1999-07-16 2002-06-17 System for effecting smoke cessation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US61142300A Continuation 1999-07-16 2000-07-07

Publications (1)

Publication Number Publication Date
US20020179102A1 true US20020179102A1 (en) 2002-12-05

Family

ID=22507255

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/174,000 Abandoned US20020179102A1 (en) 1999-07-16 2002-06-17 System for effecting smoke cessation

Country Status (6)

Country Link
US (1) US20020179102A1 (ja)
EP (1) EP1218048A4 (ja)
JP (1) JP4999245B2 (ja)
AU (1) AU777326B2 (ja)
CA (1) CA2378913C (ja)
WO (1) WO2001005459A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873584A1 (fr) * 2004-08-02 2006-02-03 Jean Jacques Hubinois Systeme de sevrage tabagique
US20140261488A1 (en) * 2013-03-15 2014-09-18 Altria Client Services Inc. Electronic smoking article
US10357060B2 (en) 2016-03-11 2019-07-23 Altria Client Services Llc E-vaping device cartridge holder
US10368581B2 (en) 2016-03-11 2019-08-06 Altria Client Services Llc Multiple dispersion generator e-vaping device
US10368580B2 (en) 2016-03-08 2019-08-06 Altria Client Services Llc Combined cartridge for electronic vaping device
US10433580B2 (en) 2016-03-03 2019-10-08 Altria Client Services Llc Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge
US10455863B2 (en) 2016-03-03 2019-10-29 Altria Client Services Llc Cartridge for electronic vaping device
US11633556B2 (en) 2017-09-22 2023-04-25 Imperial Tobacco Limited Aerosolization using two aerosol generators
US12439962B2 (en) 2016-03-11 2025-10-14 Altria Client Services Llc Multiple dispersion generator e-vaping device

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6595210B2 (en) * 2000-11-27 2003-07-22 Unisia Jecs Corporation Inhalator for administering powder composition
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
CA2447519C (en) 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
WO2003041693A1 (en) 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
CA2460343A1 (en) 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN100381083C (zh) 2003-04-29 2008-04-16 韩力 一种非可燃性电子喷雾香烟
JP2007516404A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
CN2719043Y (zh) 2004-04-14 2005-08-24 韩力 雾化电子烟
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
CN201067079Y (zh) 2006-05-16 2008-06-04 韩力 仿真气溶胶吸入器
EP2086527A4 (en) * 2006-12-01 2010-03-03 Aradigm Corp SYSTEMS FOR IMPACT OF TOBACCO ABSTINENCE
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CN201379072Y (zh) 2009-02-11 2010-01-13 韩力 一种改进的雾化电子烟
US20120048963A1 (en) 2010-08-26 2012-03-01 Alexza Pharmaceuticals, Inc. Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
HUE064899T2 (hu) 2015-03-11 2024-04-28 Alexza Pharmaceuticals Inc Antisztatikus anyagok használata a légcsatornában a termális aeroszol kondenzációs folyamat létrehozására
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019162373A1 (en) * 2018-02-26 2019-08-29 Nerudia Limited Device, system and method
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
EP3880175A4 (en) 2018-11-16 2022-08-17 Morningside Venture Investments Limited TEMPERATURE-REGULATING TRANSDERMAL DRUG DELIVERY SYSTEM
LU101510B1 (en) * 2019-12-02 2021-06-04 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of an aerosol and dispensing device
BR112023002926A2 (pt) * 2020-08-26 2023-04-25 Cila Therapeutic Inc Agentes terapêuticos inaláveis

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4393884A (en) * 1981-09-25 1983-07-19 Jacobs Allen W Demand inhaler for oral administration of tobacco, tobacco-like, or other substances
US4474191A (en) * 1982-09-30 1984-10-02 Steiner Pierre G Tar-free smoking devices
US4715387A (en) * 1985-08-23 1987-12-29 The Regents Of The Univ. Of California Aerosol for use in the reduction of tobacco smoking
US4735217A (en) * 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4765348A (en) * 1986-12-12 1988-08-23 Brown & Williamson Tobacco Corporation Non-combustible simulated cigarette device
US4793366A (en) * 1985-11-12 1988-12-27 Hill Ira D Nicotine dispensing device and methods of making the same
US4800903A (en) * 1985-05-24 1989-01-31 Ray Jon P Nicotine dispenser with polymeric reservoir of nicotine
US4813437A (en) * 1984-01-09 1989-03-21 Ray J Philip Nicotine dispensing device and method for the manufacture thereof
US4917120A (en) * 1986-05-21 1990-04-17 Advanced Tobacco Products, Inc. Nicotine impact modification
US4945929A (en) * 1986-06-18 1990-08-07 British-American Tobacco Co., Ltd. Aerosol device simulating a smoking article
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5834011A (en) * 1988-02-19 1998-11-10 The Regents Of The University Of California Method for aiding in the reduction of incidence of tobacco smoking
US5894841A (en) * 1993-06-29 1999-04-20 Ponwell Enterprises Limited Dispenser
US5906202A (en) * 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US5935604A (en) * 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
US5939100A (en) * 1993-11-01 1999-08-17 Pharmacia And Upjohn Ab Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3241437A1 (de) * 1982-11-10 1984-05-10 Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt Mittel zum zwecke der raucherentwoehnung und/oder fuer nebenwirkungsfreien nikotingenuss bei suchtrauchern
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
DK0557129T3 (da) * 1992-02-20 1997-04-14 Wielligh Johannes Louw Kot Von Produkt til at hjælpe rygere med at holde op med at ryge
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US6196218B1 (en) * 1999-02-24 2001-03-06 Ponwell Enterprises Ltd Piezo inhaler

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4393884A (en) * 1981-09-25 1983-07-19 Jacobs Allen W Demand inhaler for oral administration of tobacco, tobacco-like, or other substances
US4474191A (en) * 1982-09-30 1984-10-02 Steiner Pierre G Tar-free smoking devices
US4813437A (en) * 1984-01-09 1989-03-21 Ray J Philip Nicotine dispensing device and method for the manufacture thereof
US4800903A (en) * 1985-05-24 1989-01-31 Ray Jon P Nicotine dispenser with polymeric reservoir of nicotine
US4715387A (en) * 1985-08-23 1987-12-29 The Regents Of The Univ. Of California Aerosol for use in the reduction of tobacco smoking
US4793366A (en) * 1985-11-12 1988-12-27 Hill Ira D Nicotine dispensing device and methods of making the same
US4917120A (en) * 1986-05-21 1990-04-17 Advanced Tobacco Products, Inc. Nicotine impact modification
US4945929A (en) * 1986-06-18 1990-08-07 British-American Tobacco Co., Ltd. Aerosol device simulating a smoking article
US4735217A (en) * 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4765348A (en) * 1986-12-12 1988-08-23 Brown & Williamson Tobacco Corporation Non-combustible simulated cigarette device
US5834011A (en) * 1988-02-19 1998-11-10 The Regents Of The University Of California Method for aiding in the reduction of incidence of tobacco smoking
US5400808A (en) * 1990-06-08 1995-03-28 Pharmacia Biosystems Aktiebolag Nicotine-impermeable container and method of fabricating the same
US5501236A (en) * 1990-06-08 1996-03-26 Pharmacia Ab Nicotine-impermeable container and method of fabricating the same
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5746227A (en) * 1993-02-08 1998-05-05 Advanced Therapeutic Products, Inc. Dry powder delivery system
US5935604A (en) * 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
US5894841A (en) * 1993-06-29 1999-04-20 Ponwell Enterprises Limited Dispenser
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5721257A (en) * 1993-08-04 1998-02-24 Pharmacia & Upjohn Ab Method and therapeutic system for smoking cessation
US5939100A (en) * 1993-11-01 1999-08-17 Pharmacia And Upjohn Ab Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
US5906202A (en) * 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873584A1 (fr) * 2004-08-02 2006-02-03 Jean Jacques Hubinois Systeme de sevrage tabagique
US20140261488A1 (en) * 2013-03-15 2014-09-18 Altria Client Services Inc. Electronic smoking article
US12178234B2 (en) 2016-03-03 2024-12-31 Altria Client Services Llc Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge
US12446613B2 (en) 2016-03-03 2025-10-21 Altria Client Services Llc Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge
US12420034B2 (en) 2016-03-03 2025-09-23 Altria Client Services Llc Cartridge for electronic vaping device
US10433580B2 (en) 2016-03-03 2019-10-08 Altria Client Services Llc Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge
US10455863B2 (en) 2016-03-03 2019-10-29 Altria Client Services Llc Cartridge for electronic vaping device
US20200008494A1 (en) 2016-03-03 2020-01-09 Altria Client Services Llc Cartridge for electronic vaping device
US12245632B2 (en) 2016-03-08 2025-03-11 Altria Client Services Llc Combined cartridge for electronic vaping device
US10368580B2 (en) 2016-03-08 2019-08-06 Altria Client Services Llc Combined cartridge for electronic vaping device
US12446622B2 (en) 2016-03-08 2025-10-21 Altria Client Services Llc Combined cartridge for electronic vaping device
US20210219611A1 (en) 2016-03-08 2021-07-22 Altria Client Services Llc Combined cartridge for electronic vaping device
US12171262B2 (en) 2016-03-08 2024-12-24 Altria Client Services Llc Combined cartridge for electronic vaping device
US12178256B2 (en) 2016-03-11 2024-12-31 Altria Client Services Llc Multiple dispersion generator e-vaping device
US10368581B2 (en) 2016-03-11 2019-08-06 Altria Client Services Llc Multiple dispersion generator e-vaping device
US12438608B2 (en) 2016-03-11 2025-10-07 Altria Client Services Llc E-vaping device cartridge holder
US12439962B2 (en) 2016-03-11 2025-10-14 Altria Client Services Llc Multiple dispersion generator e-vaping device
US10357060B2 (en) 2016-03-11 2019-07-23 Altria Client Services Llc E-vaping device cartridge holder
US12453379B2 (en) 2016-03-11 2025-10-28 Altria Client Services Llc Multiple dispersion generator e-vaping device
US12059525B2 (en) 2017-09-22 2024-08-13 Nerudia Limited Substitute smoking device comprising multiple aerosols and passive aerosol generation
US11633556B2 (en) 2017-09-22 2023-04-25 Imperial Tobacco Limited Aerosolization using two aerosol generators
US12337105B2 (en) 2017-09-22 2025-06-24 Imperial Tobacco Limited Aerosolization using two aerosol generators
US12029846B2 (en) 2017-09-22 2024-07-09 Imperial Tobacco Limited Aerosolization using two aerosol generators

Also Published As

Publication number Publication date
EP1218048A4 (en) 2009-08-26
JP4999245B2 (ja) 2012-08-15
WO2001005459A1 (en) 2001-01-25
AU777326B2 (en) 2004-10-14
CA2378913C (en) 2010-02-23
AU5931200A (en) 2001-02-05
EP1218048A1 (en) 2002-07-03
CA2378913A1 (en) 2001-01-25
JP2003504165A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
US6799576B2 (en) System for effecting smoking cessation
CA2378913C (en) System for effecting smoke cessation
US8381739B2 (en) Systems and methods for effecting cessation of tobacco use
RU2283111C2 (ru) Забуференная жидкая никотиновая композиция для легочного введения
CA2146954C (en) Breath activated nicotine inhalers
EP1409049B9 (en) Device for the administration of a substance
US6102036A (en) Breath activated inhaler
WO2008069972A2 (en) Systems for effecting cessation of tobacco use
US20080138294A1 (en) Systems and methods for effecting cessation of tobacco use
US7767698B2 (en) Formulation and use thereof
WO2014150245A1 (en) Methods for inhalation of smoke-free nicotine
US20080138399A1 (en) Dual release nicotine formulations, and systems and methods for their use
US20090004249A1 (en) Dual release nicotine formulations, and systems and methods for their use
US20110182831A1 (en) Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
CN101583354A (zh) 用于终止烟草使用的系统
WO1995011678A9 (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
WO1995011678A1 (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
EP4398964A1 (en) Delivery devices and compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: ARADIGM CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FARR, STEPHEN J.;REEL/FRAME:013040/0027

Effective date: 20010107

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION